Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3

Regeneron's Melanoma Combo Fails Phase 3 Against Keytruda

Regeneron's investigational LAG-3 inhibitor fianlimab, in combination with its FDA-approved PD-1 blocker Libtayo, failed to demonstrate significant survival benefits as a first-line treatment for unresectable or metastatic melanoma in a Phase 3 trial. The combination regimen, tested against Merck's Keytruda, showed median progression-free survival (PFS) of 11.5 months for the high-dose and 9.6 months for the low-dose, compared to 6.4 months for Keytruda. However, the treatment difference did not reach statistical significance for either test arm. This late-stage miss has significantly shaken analyst confidence in Regeneron's clinical execution and pipeline.

• The Phase 3 study evaluated Regeneron's fianlimab plus Libtayo combination against Merck's Keytruda as a first-line treatment for patients with unresectable or metastatic melanoma. Results showed a median progression-free survival (PFS) of 11.5 months for the high-dose combination and 9.6 months for the low-dose, compared to 6.4 months for patients treated with Keytruda. Crucially, the treatment difference for both test arms failed to reach statistical significance.
• The trial's failure led to a 10% drop in Regeneron's stock, falling to $624 before Monday's opening bell. Analysts from BMO Capital Markets and Truist Securities expressed strong disappointment, labeling the readout a 'mishap' and noting that 'even more pressure has been placed on the company’s pipeline.' This outcome has raised significant concerns among investors regarding Regeneron's R&D execution and the emergence of strong pipeline drivers.
• Regeneron attributed the miss to 'late-separation in PFS curves' and indicated a trend toward improvement in overall survival. However, analysts remained unconvinced, emphasizing that 'close does not count.' This setback follows a previous late-stage stumble in May 2025 with itepekimab in chronic obstructive pulmonary disease, further intensifying investor frustration with the company's clinical development track record.

Unpacking the Fianlimab + Libtayo Phase 3 Melanoma Results

The PROMIT trial (NCT04225390) investigated a novel approach to overcome immunotherapy resistance in metastatic melanoma patients. This prospective multicenter phase II study enrolled 53 patients with BRAF wild-type metastatic melanoma who exhibited primary resistance to immune checkpoint inhibitors (ipilimumab plus nivolumab or pembrolizumab). The intervention involved two doses of dacarbazine at 850 mg/m² administered intravenously on days 1 and 21, followed by re-challenge with the same ICI therapy one week after the second DTIC dose. Among the 38 patients evaluable for efficacy, the overall objective response rate was 18.4% (95% CI 0.08-0.34), with 7 patients achieving partial response and a disease control rate of 36.8%. The treatment demonstrated a favorable safety profile, with grade 3 or higher adverse events occurring in only 10.4% of patients, no new safety signals observed, and overall good tolerability.

The KEYNOTE-716 trial (NCT03553836) represents a landmark study in adjuvant melanoma therapy, demonstrating sustained benefits of pembrolizumab in completely resected stage IIB or IIC cutaneous melanoma. This multicenter, double-blind, phase 3 randomized trial enrolled 976 participants aged 12 years or older, with 487 assigned to pembrolizumab 200 mg (2 mg/kg for pediatric participants) and 489 to placebo, administered every 3 weeks for up to 17 cycles. After a median follow-up of 52.8 months, pembrolizumab significantly extended recurrence-free survival, with median RFS not reached versus 59.2 months with placebo (hazard ratio 0.65; 95% CI 0.52-0.80), and 48-month RFS rates of 68.7% versus 56.5%. Safety analysis revealed immune-mediated severe skin reactions in 16 of 483 participants (3.3%) in the pembrolizumab group versus 3 of 486 (0.6%) in the placebo group, with grade 3 or 4 reactions occurring in 2.9% versus 0.6% respectively, though these reactions were generally manageable.

The Morpheus-Melanoma trial evaluated innovative combination approaches in stage III resectable melanoma through a phase 1b/2 randomized umbrella design. The study compared tobemstomig (anti-PD-1/anti-LAG-3 bispecific antibody) alone or in combination with tiragolumab (anti-TIGIT antibody), and atezolizumab plus tiragolumab, against the standard combination of nivolumab plus ipilimumab. While tobemstomig monotherapy achieved similar pathological response rates to nivolumab plus ipilimumab (80.0% versus 77.3%), it demonstrated substantially improved safety with only 2.5% experiencing grade 3 or higher treatment-related adverse events compared to 22.7% with the standard combination, and no treatment discontinuations due to adverse events versus 13.6% with nivolumab plus ipilimumab.

Persistent Challenges in Unresectable or Metastatic Melanoma Treatment

Despite significant advances in melanoma treatment over the past decade, substantial challenges remain in managing unresectable or metastatic disease. These limitations continue to drive mortality rates, with at least half of all advanced melanoma patients eventually progressing and succumbing to their disease. Treatment failures often occur as tumors develop resistance mechanisms and rapidly spread throughout the body.

• Short-lived therapeutic responses: Targeted therapies like vemurafenib produce high levels of tumor shrinkage and survival benefits in BRAF V600E mutant melanomas, but these responses are typically transient despite initial efficacy

• Limited response rates across treatment modalities: Standard chemotherapy such as dacarbazine has not achieved satisfactory response rates for metastatic lesions, while overall lack of response to existing treatment options continues to challenge clinical outcomes

• Incomplete patient response and poor survival outcomes: Not all patients respond to available treatments, with approximately 50% of patients with metastatic cutaneous melanoma and almost all patients with uveal melanoma metastases dying from their disease

• Acquired drug resistance: Development of resistance mechanisms is associated with poor prognosis in advanced-stage melanoma, leading to treatment failure and rapid disease progression

• Brain metastases management challenges: Melanoma frequently spreads to the brain, resulting in rapid deterioration in quality and quantity of life, while patients with melanoma brain metastases have historically been excluded from clinical trials, limiting treatment insights

• Therapeutic limitations requiring improvement: Key areas include tolerability and safety profiles, progression-free survival rates, and duration of response to decrease drug resistance development

• Combination therapy complexity: Potential synergy between oncogene-directed therapy and immunotherapy requires rational design of medical protocols, including optimal sequence and timing of agent administration, drug selectivity, and compatibility considerations

• Resistance to conventional treatments: Melanoma demonstrates resistance to radiation therapy, while complete surgical resection in locally advanced disease remains challenging and chemotherapy is not curative

• Limited options for specific mutations: Patients with NRAS-mutated melanoma face particularly limited therapeutic options, with immunotherapy currently being the treatment of choice despite poor prognosis

• Precision and toxicity concerns: Conventional therapeutic strategies often suffer from limited precision, resulting in significant off-target toxicity or failure to prevent disease recurrence

Regeneron's LAG-3 Setback Reshapes First-Line Melanoma Strategy

The recent Phase 3 trial results for Regeneron's fianlimab in combination with Libtayo, failing to achieve statistical significance in first-line unresectable or metastatic melanoma, send a clear signal across the oncology landscape. While immune checkpoint inhibitors have revolutionized melanoma treatment, with anti-PD-1 monotherapy and combinations like nivolumab plus ipilimumab (anti-CTLA-4) demonstrating superior outcomes, the bar for new entrants is exceptionally high. The rationale for combining LAG-3 and PD-1 blockade is strong, targeting distinct pathways of T-cell exhaustion to enhance antitumor immunity. Indeed, the success of nivolumab plus relatlimab, another PD-1/LAG-3 combination, in significantly improving progression-free survival in this exact setting, validates the therapeutic concept.

However, fianlimab's outcome suggests that not all LAG-3 inhibitors or combination strategies are created equal. Despite a numerical improvement in PFS, the inability to reach statistical significance against Keytruda highlights the critical need for robust and undeniable clinical benefit to justify a new therapy in a crowded market. This event will likely prompt a re-evaluation of fianlimab's development path, potentially shifting focus to:

• Later-line settings: Where the unmet need might be higher, and the competitive landscape less intense.

• Other tumor types: Preclinical and early clinical data suggest LAG-3 inhibition could be beneficial in indications like glioblastoma, dMMR colon cancer, head and neck squamous cell carcinoma, or uveal melanoma, where the immune microenvironment or patient populations might be more receptive.

• Biomarker-driven strategies: The search for predictive biomarkers, such as specific T-cell subsets or interferon-gamma signatures, becomes even more crucial to identify patients most likely to respond, thereby optimizing trial design and improving success rates.

The challenge remains to overcome resistance and non-responsiveness, which affect a significant percentage of patients receiving existing ICIs. This setback for fianlimab underscores that while combination immunotherapy holds immense promise, careful patient selection, rigorous trial design, and a deep understanding of tumor-immune interactions are paramount for translating preclinical promise into clinical success. The future of LAG-3 inhibition will depend on identifying its optimal niche and demonstrating clear, statistically significant advantages in well-defined patient populations.